Stem Cell Therapy for Geographic Atrophy: Is It Real?
Stem Cell Therapy for Geographic Atrophy at a Glance
The research is real. The treatment is not for sale. The FDA says stem cell and other regenerative medicine therapies have not been approved to treat macular degeneration or blindness.1 The only stem cell products it has approved in the United States are blood-forming cells from cord blood, used for blood disorders.1 So the one lawful way to get cell therapy for your retina today is inside a research study. Several small studies have started. One has reported gains on the eye chart in a handful of people.2 That result is early, and the study was far too small to settle the question.
This page is for you if you have geographic atrophy and you have seen a headline or an ad about stem cells. Geographic atrophy is a potentially debilitating type of dry age-related macular degeneration, in which regions of cells in the retina waste away and die, leaving a growing blind spot in the field of vision.3 There is no treatment for late dry macular degeneration, though there are ways to make the most of the vision you still have.4 Neither of the two medicines now available for geographic atrophy has been shown to improve eyesight or restore lost vision.3 That gap is why the stem cell idea draws so much hope, and why it draws people selling false hope.
Start with a retina specialist who can confirm your stage with imaging and tell you whether a study near you is enrolling. Bring your imaging history, your medication list, and any ad you have been shown. If a clinic offers you cells for cash today, treat that as a reason to pause. Nothing here replaces that visit with your own eye doctor.
What Stem Cell Therapy for the Retina Actually Means
Under your retina sits a thin support layer called the retinal pigment epithelium, or RPE. In a healthy eye these cells feed and clean up after the photoreceptors, which are the light-sensing cells. In geographic atrophy the support cells die first, the photoreceptors above them break down, and vision fades.5 Cell therapy aims to lay down healthy support cells in the bare patches, so the light-sensing cells hold on longer.
Cell therapy is not the quick office injection used for wet macular degeneration. Those shots put a drug into the jelly of the eye in a few minutes. A cell transplant is operating-room surgery that places living cells in a precise layer under the retina. Anyone offering a two-minute stem cell shot in a chair is not describing what researchers study.
Study teams use two starting points. One grows cells from a donated cell line kept in a lab. The other turns a participant's own blood cells into stem cells, coaxes them into retinal support cells, and grows them on a small patch for implanting.6 Neither uses fat taken from your body during the same visit. That fat shortcut is the version sold by cash clinics.
How a Retinal Cell Transplant Is Meant to Work
The operation starts like other retina surgery. A surgeon clears the jelly from the middle of the eye, then eases a droplet of cells or a tiny patch of tissue into the space under the retina, next to the atrophy. It is delicate work, and the field is still learning to do it well. One company study of about 60 people is set up to work out how best to deliver the cells surgically, and to check safety and early activity.7
The hope is modest and specific. Transplanted support cells would need to survive, settle into the right layer, and keep nearby light-sensing cells alive longer. Slowing the spread of an atrophy patch would count as a real win on its own. Whether any of that shows up as vision you would notice is what larger studies still have to answer, and none of them have finished.
What the Research Has Actually Shown So Far
The most encouraging finding so far is about safety, not vision. In the low-dose first group of a first-in-human trial, six people with dry macular degeneration had cells injected under the retina. The team reported no significant inflammation, no tumor, and no serious adverse events tied to the product.2 Six people is a very small group, and short follow-up cannot rule out slow problems such as abnormal cell growth. Still, that early signal let the study move to a higher dose.
News coverage often blends very different projects together. The table below sorts the two main routes by the stage each has actually reached.
| Approach | Stage reached | What that means for you |
|---|---|---|
| Donor cell line, placed under the retina | Early and mid-stage studies, single-arm, no comparison group7 | Open to you only by joining a study |
| Cells grown from your own blood, implanted as a patch | Earliest safety stage, about 20 people planned6 | Very few slots, strict entry rules |
Some numbers sound dramatic on their own. In that same six-person study, the three worse-seeing participants improved by an average of about 22 letters on the eye chart at 12 months.2 Read that slowly. Three people, no comparison group, and everyone knew who got the cells. Eyes that start with poor vision also swing more from visit to visit, so an average built from three of them can move a long way for other reasons.
Honest grading matters more than enthusiasm here. The studies behind the results above are small and open-label, with no untreated comparison group. That is the weakest design that still counts as clinical evidence. It is normal at this stage of research and it is not a knock on the scientists. It does mean nobody can yet tell you how much benefit to expect, how long it lasts, or who it helps.
Who Might Qualify for a Stem Cell Study
Teams look for people whose atrophy is easy to measure but who still have retina worth protecting. The National Eye Institute study is recruiting people aged 55 and older who have geographic atrophy with vision loss, and it excludes eyes that have had wet macular degeneration.6 Entry rules differ from study to study, so being turned down by one does not close the door on another.
Screening goes well beyond a routine eye exam. In that study, screening includes retinal imaging, a dye photograph of the blood vessels in your eye, a test of how your retina answers light, blood work, a chest x-ray, and a heart tracing.6 Participants also sign up for at least 14 visits over roughly five and a half years.6 That commitment is part of the decision, so weigh it before you start.
In the National Eye Institute study, the transplant is done in one eye only.6 That is deliberate. If something goes wrong, your other eye is untouched, and it also gives researchers a comparison. So if anyone proposes treating both of your eyes on the same day with cells, treat it as a serious warning sign and walk away. In the published report of harm at a cash clinic, all three patients developed severe vision loss in both eyes.8
Who Should Not Pursue Stem Cell Treatment Right Now
Wet macular degeneration happens when abnormal blood vessels grow in the back of the eye and damage the macula. It is a less common type of late macular degeneration that usually causes faster vision loss, and treatment options are available for it.4 The National Eye Institute study excludes an eye that has had wet macular degeneration.6 If your eye has converted, the wet disease is treated first. Your retina specialist makes that call with your scans in front of them.
A cell transplant is real surgery, so the usual surgical questions apply. Your team will ask about blood thinners, diabetes control, any active infection, whether you can lie flat, and whether you can reach frequent visits. Any of those answers can change the timing, or the decision. None of it is a judgment about you. It is a judgment about the balance of risk and possible benefit for your eye right now.
This is the clearest line on the page. The FDA states that if you are being charged for these products, or offered them outside a clinical trial, you are likely being deceived and offered a product illegally.1 A legitimate study does not bill you for the experimental cells. If the answer to 'what does it cost' is a price list, stop and take the details to your retina specialist.
What Happens When You Ask Your Retina Specialist About It
Your visit starts with the imaging already used to track geographic atrophy: a scan of the retinal layers and a picture that maps the size and shape of the atrophy patch. Those images show how fast your patch is growing. Ask to see them on screen, because watching your own scan change over a year makes the rest of the conversation concrete.
Get the practical answers before you agree. Which institution runs the study, and who leads it? What happens if the cells fail, and who pays to treat a complication? Can you withdraw later, and what follow-up continues if you do? A well-run study answers all of this without hesitation and hands you a consent document to read at home.
Sponsors usually cover the experimental product and the visits the study requires. Travel, time off work, and your routine eye care often stay with you. Coverage varies, so ask for specifics rather than assuming. If flying to a distant center several times a year is not realistic, say so early. Honest logistics up front beat dropping out halfway through.
Recovery After Cell Transplant Surgery in a Study
Recovery follows the pattern of other surgery inside the eye, and your surgical team sets the exact instructions. Ask them in advance about eye drops, how long to avoid lifting and bending, whether you will need to hold your head in a set position, and when blurred vision should settle. Ask which sensations are expected and which should make you call. Keep that answer written down.
People underestimate the follow-up. In the National Eye Institute study, participants return for at least 14 visits over about five and a half years, repeating the screening tests as they go.6 That intensity is the point. It is how a new therapy earns its evidence, and how a slow problem gets caught. Going in expecting a multi-year relationship with the study center sets a fairer frame than expecting one operation and a discharge letter.
How to Tell a Real Study From a Clinic Selling Hope
Ads leave this part out. Three patients developed severe vision loss in both eyes after injections into the eye of cells prepared from their own fat at one such clinic in the United States. Their vision ranged from 20/30 to 20/200 before the injection, and from 20/200 to no light perception a year after it.8 Similar blinding complications, including severe retinal detachment, have been reported from more than one unrelated clinic.9 A federal court later granted a permanent injunction stopping the Florida clinic involved from distributing those fat-derived products until it follows the law.10 None of that is a reason to give up on the science. It is a reason to use the two simple checks below, which screen out this kind of offer before any needle comes near your eye.
The pattern repeats often enough to spot. Be very cautious about any of these:
- A price for the cells themselves, especially thousands of dollars paid up front.
- An offer to treat both eyes on the same day.
- Cells taken from your own fat and injected during the same visit.
- Testimonials and before-and-after photos in place of published results.
- A claim that a trial-registry listing, or registration with the FDA, makes the product lawful.
On that last point, the FDA warns that a listing in the ClinicalTrials.gov database, or a firm registering its product, does not mean the product is legally marketed.1
Three checks catch most problems. Ask which academic center or sponsor runs the study, then look it up yourself. Ask whether the study runs under an FDA investigational new drug application, which the agency says is required to give these products legally.1 Then take the consent document to your own retina specialist before signing. A team that resists all three questions has told you what you need to know.
Risks, Costs, and a Realistic Outlook
Even in expert hands, opening the eye carries real risk. The known risks of vitrectomy, the operation used to reach the back of the eye, include infection, bleeding, a torn or detached retina, and raised eye pressure.11 A cataract forming later is also common after this surgery, especially in people over 50.11 Many of these can be dealt with when they are caught early, which is exactly why study follow-up is so frequent.
Something is available now, with honest limits. Geographic atrophy affects roughly one million people in the United States.3 The two injectable medicines available for it, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), slow the growth of the atrophy on scans, but neither has been shown to improve eyesight or restore lost vision.3 They also carry risks, including inflammation, higher eye pressure, a shift to wet macular degeneration, and rare severe inflammation of the retinal vessels.3 Whether that trade suits you is a real judgment call to make with your specialist.
Nobody can give you a date. What can be said is that the studies now recruiting are early-stage safety studies, and the larger comparison studies needed for approval have not been finished. The National Eye Institute study alone is scheduled to follow its participants into 2029.6 Planning around care that exists today, while watching the research, beats waiting for a therapy with no arrival date.
When to Call Your Eye Doctor
Some changes should not wait for your next appointment. Call your eye doctor the same day, or go to an emergency room if you cannot reach anyone, for any of these:
- A sudden shower of new floaters or flashing lights.
- A dark curtain or shadow moving across part of your vision.
- A sudden drop in vision, or sudden severe eye pain.
- Growing redness, discharge, or worsening pain after any eye procedure.
New or increasing floaters, flashing lights, or a curtain crossing the vision can mean a retinal tear or a detaching retina, and they call for a prompt dilated exam rather than waiting.12 Caught early, many retinal tears can be sealed in the office, which is exactly why the same-day call matters.
Other changes are worth reporting without alarm. More blur at the center of your vision, or new trouble reading in dim light, deserves a call within a week. One change belongs higher up that list. Straight lines looking wavy is a warning sign for late macular degeneration, and the National Eye Institute says to see your eye doctor right away if you notice it.4 Usually a phone call and an earlier appointment are all that follows.
Geographic atrophy belongs with a retina specialist, an eye surgeon with extra training in the back of the eye. If you see an optometrist or a general ophthalmologist, ask for a referral so someone is tracking your atrophy measurements over time. That specialist is also the right person to judge whether a study makes sense for you.
Common Questions About Stem Cell Therapy for Geographic Atrophy
Not as an approved treatment. The only lawful route is joining a clinical study that runs under FDA oversight, and those studies have limited slots and strict entry rules. Clinics advertising stem cells for macular degeneration for a fee sit outside that framework. If you want to explore this, ask your retina specialist to help you look for legitimate studies rather than answering an ad.
Nobody can promise that, and no page should. The realistic goal researchers describe is protecting the retina you still have and slowing the spread of the atrophy. A few early participants gained letters on the eye chart, but those were tiny groups without a comparison arm. Treat any offer that promises restored vision as a reason to be more careful, not less.
The answer splits in two. In carefully run studies, early safety reports have been reassuring so far, with no serious adverse events tied to the product in the first small groups. Outside those studies, injections marketed as stem cell treatment have caused severe, lasting vision loss. The setting matters as much as the cells. That difference is the most useful thing to take from this page.
Sponsors usually cover the experimental product and the visits the study requires, while travel, time away from work, and routine eye care stay with you. Costs and reimbursement differ by sponsor, so ask for specifics in writing. What should never happen is a charge for the experimental cells themselves. That is a signal you are not looking at a legitimate study.
They solve different problems. Gene therapy delivers genetic instructions so your own cells make a missing or helpful protein, and it is aimed mostly at inherited retinal disease and at easing the injection burden in wet macular degeneration. Cell therapy replaces missing cells outright. Both are active fields, studied separately. Neither is available for geographic atrophy outside research.
Please do not make that change on your own. Stopping monitoring or ongoing treatment because something better might arrive later is a common way people lose ground. Bring the question to your retina specialist, who can weigh what your scans show against what is realistically coming. Any change to your plan should be a shared decision, made with your current imaging in view.
More Questions About Studies and Cash Clinics
Start with your retina specialist, who often knows which centers in your region are recruiting. Academic eye centers and the National Eye Institute list their studies publicly, and a registry entry names the sponsor, the site, and the entry rules. Use the registry to prepare questions, not as proof of legitimacy, since the FDA warns that a listing alone does not make a product lawful.
Not automatically, and assuming so has caused real harm. The injections that blinded patients used cells from the person's own fat. Coming from your body does not make a cell the right type for the retina, and it does not make the injection safe. What matters is whether the product was made to a controlled standard and tested under regulatory oversight.
It is a recognized theoretical concern, which is why studies watch for it for years. Stem cells can in principle keep dividing, so growth in the wrong place is a risk regulators take seriously. In the small published groups so far, no tumor has been reported. Small groups and short follow-up cannot rule the risk out yet, which is one reason participants are followed for half a decade.
Take it seriously as their experience, and still be cautious. Vision fluctuates, expectation shapes what people notice, and one story cannot separate a real effect from chance. Ask what was measured before and after, by whom, and whether any of it was published. If your relative is doing well, that is good news, and it is not evidence you can lean on for your own eye.
- What do my scans show about how fast my geographic atrophy is spreading?
- Am I anywhere near the entry rules for a cell therapy study, and is any center near me recruiting?
- Given my eye and my general health, what would surgery inside my eye risk for me?
- Would one of the approved injections make sense for me now, and what would it realistically do?
- Here is an offer I was sent: what would you want to know before I answered it?
- What symptoms should make me call you the same day?
- U.S. Food and Drug Administration (FDA) (2024). Important Patient and Consumer Information About Regenerative Medicine Therapies.
- Cell Stem Cell 2025;32(11):1659-1670, via PubMed (2025). Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes.
- American Academy of Ophthalmology, EyeSmart (reviewed by Rahul N. Khurana, MD) (2025). What to Know About Syfovre and Izervay for Geographic Atrophy.
- National Eye Institute (NIH) (2024). Age-Related Macular Degeneration (AMD).
- National Eye Institute (NIH) research news (2018). NIH discovery brings stem cell therapy for eye disease closer to the clinic.
- ClinicalTrials.gov, National Eye Institute (NIH) (2026). A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration (NCT04339764).
- ClinicalTrials.gov, Genentech, Inc. (2026). A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT05626114).
- New England Journal of Medicine 2017;376(11):1047-1053, via PubMed (2017). Vision Loss after Intravitreal Injection of Autologous 'Stem Cells' for AMD.
- Oncotarget 2017;8(53):90636-90637, via PubMed Central (2017). Unproven stem cell therapy for macular degeneration.
- U.S. Food and Drug Administration (FDA) (2019). Statement on stem cell clinic permanent injunction and FDA's ongoing efforts to protect patients from risks of unapproved products.
- American Academy of Ophthalmology, EyeSmart (2024). What Are Vitrectomy Surgery Risks?.
- American Academy of Ophthalmology, Preferred Practice Pattern (2024). Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern.